Skip to main content

Table 2 Clinical parameters and laboratory results in the baseline and follow-up visits

From: The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients

Variables Baseline (mean± SD) FU (mean± SD) P value
SBP (mmHg) 118.9 ± 8.5 115.8 ± 7.5 0.001
DBP (mmHg) 71 ± 7.8 69.1 ± 8.1 0.084
HR (bpm) 81.4 ± 12.3 85.2 ± 13.7 0.012
Weight (kg) 72.4 ± 9.7 71.4 ± 9.4 0.117
BMI (kg/m2) 26.4 ± 2.7 26.2 ± 2.61 0.256
Hb (g/dl) 12.8 ±0.8 12.1 ± 1.1 <0.001
Platelets (× 109/L) 348.5 ± 98.9 333.3 ± 100.6 0.007
Creatinine (mg/dl) 0.8 ± 0.1 0.8 ± 0.1 0.779
NT-pro BNP, median (range), pg/ml 34.4 (446.2) 73.5 (956.4) <0.001
Delta NT-pro BNP, median (range), pg/ml 16.2 (535.6)
  1. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HR heart rate, Hb hemoglobin